Next Article in Journal
The Neuroprotective Marine Compound Psammaplysene A Binds the RNA-Binding Protein HNRNPK
Next Article in Special Issue
Myticalins: A Novel Multigenic Family of Linear, Cationic Antimicrobial Peptides from Marine Mussels (Mytilus spp.)
Previous Article in Journal
Saccharomonopyrones A–C, New α-Pyrones from a Marine Sediment-Derived Bacterium Saccharomonospora sp. CNQ-490
Article Menu
Issue 8 (August) cover image

Export Article

Open AccessArticle
Mar. Drugs 2017, 15(8), 240; doi:10.3390/md15080240

Anti-Coagulant and Anti-Thrombotic Properties of Blacklip Abalone (Haliotis rubra): In Vitro and Animal Studies

1
UQ Diamantina Institute, Translational Research Institute, Faculty of Medicine, The University of Queensland, 37 Kent Street Woolloongabba, Brisbane, QLD 4102, Australia
2
CSIRO Agriculture and Food, 306 Carmody Road, St Lucia, Brisbane, QLD 4067, Australia
3
Royal Brisbane & Women’s Hospital Campus, University of Queensland Centre for Clinical Research, The University of Queensland, Herston, Brisbane, QLD 4029, Australia
Glenda C. Gobe and Simone A. Osborne contributed equally to this research.
*
Author to whom correspondence should be addressed.
Received: 14 June 2017 / Revised: 24 July 2017 / Accepted: 27 July 2017 / Published: 4 August 2017
(This article belongs to the Special Issue Target Identification of Marine Products)
View Full-Text   |   Download PDF [616 KB, uploaded 4 August 2017]   |  

Abstract

Sulphated polysaccharides with anti-thrombotic and anti-coagulant activities have been found in various marine biota. In this study, a previously characterised anti-thrombotic and anti-coagulant extract from blacklip abalone was fractionated by anion exchange chromatography (AEC), pooled (on a sulphated polysaccharide basis) and administered to Wistar rats via oral gavage (N = 8) for assessment as an oral therapeutic. To ensure that the preparation had anti-coagulant activity prior to oral administration, it was assessed in rat blood by thromboelastography (TEG) significantly increasing reaction (R) time (or time until clot formation). Following in vitro confirmation of anti-coagulant activity, 40 mg of the preparation was orally administered to rats with blood samples collected at 2, 4, and 6 h post-gavage. Assessment of all blood samples by TEG showed some prolongation of R time from 355 to 380 s after 4 h. Dosing of the post-gavage blood samples with the abalone preparation to confirm anti-thrombotic activity in vitro revealed residual anti-coagulant activity, further suggesting that oral administration did increase anti-coagulant potential in the collected blood but that bioavailability was low. Assessment of tissues and haematological parameters showed no obvious harmful effects of the abalone preparation in animals. In summary, even though oral administration of fractionated and pooled blacklip abalone extract to rats delayed clotting after 4 h, bioavailability of the preparation appeared to be low and may be more appropriate for intravenous administration as an anti-thrombotic or anti-coagulant therapeutic. View Full-Text
Keywords: marine processing waste; blacklip abalone; anti-thrombotic and anti-coagulant activity marine processing waste; blacklip abalone; anti-thrombotic and anti-coagulant activity
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Suleria, H.A.R.; Masci, P.P.; Zhao, K.-N.; Addepalli, R.; Chen, W.; Osborne, S.A.; Gobe, G.C. Anti-Coagulant and Anti-Thrombotic Properties of Blacklip Abalone (Haliotis rubra): In Vitro and Animal Studies. Mar. Drugs 2017, 15, 240.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Mar. Drugs EISSN 1660-3397 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top